Your browser doesn't support javascript.
loading
Past and current cause-specific mortality in Eisenmenger syndrome.
Hjortshøj, Cristel M Sørensen; Kempny, Aleksander; Jensen, Annette Schophuus; Sørensen, Keld; Nagy, Edit; Dellborg, Mikael; Johansson, Bengt; Rudiene, Virginija; Hong, Gu; Opotowsky, Alexander R; Budts, Werner; Mulder, Barbara J; Tomkiewicz-Pajak, Lidia; D'Alto, Michele; Prokselj, Katja; Diller, Gerhard-Paul; Dimopoulos, Konstantinos; Estensen, Mette-Elise; Holmstrøm, Henrik; Turanlahti, Maila; Thilén, Ulf; Gatzoulis, Michael A; Søndergaard, Lars.
Afiliação
  • Hjortshøj CMS; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
  • Kempny A; Biomedical Research Unit, Adult Congenital Heart Centre, National Centre for Pulmonary Hypertension, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College London, London, UK.
  • Jensen AS; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
  • Sørensen K; Department of Internal Medicine, Aalborg University Hospital, Farsoe, Denmark.
  • Nagy E; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Dellborg M; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Johansson B; Department of Cardiology, Sahlgrenska Academy, University of Göteborg, Sweden.
  • Rudiene V; Department of Cardiology, Norrland University Hospital, Umeå, Sweden.
  • Hong G; Department of Cardiology, Vilnius University Hospital, Vilnius, Lithuania.
  • Opotowsky AR; Department of Paediatric Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
  • Budts W; Boston Adult Congenital Heart (BACH), Pulmonary Hypertension Service, Boston Children's Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Mulder BJ; Department of Cardiology, University Hospitals Leuven, Belgium.
  • Tomkiewicz-Pajak L; Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
  • D'Alto M; Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.
  • Prokselj K; Department of Cardiology, Second University of Naples, Italy.
  • Diller GP; Department of Cardiology, University Medical Center Ljubljana, Slovenia.
  • Dimopoulos K; Biomedical Research Unit, Adult Congenital Heart Centre, National Centre for Pulmonary Hypertension, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College London, London, UK.
  • Estensen ME; Biomedical Research Unit, Adult Congenital Heart Centre, National Centre for Pulmonary Hypertension, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College London, London, UK.
  • Holmstrøm H; Department of Cardiology, Rikshospitalet, Oslo, Norway.
  • Turanlahti M; Department of Paediatric Cardiology, Rikshospitalet, Oslo, Norway.
  • Thilén U; Pediatric Cardiology, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.
  • Gatzoulis MA; Department of Cardiology, Lund University Hospital, Lund, Sweden.
  • Søndergaard L; Biomedical Research Unit, Adult Congenital Heart Centre, National Centre for Pulmonary Hypertension, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College London, London, UK.
Eur Heart J ; 38(26): 2060-2067, 2017 Jul 07.
Article em En | MEDLINE | ID: mdl-28430906
ABSTRACT

AIMS:

Eisenmenger syndrome (ES) is associated with considerable morbidity and mortality. Therapeutic strategies have changed during the 2000s in conjunction with an emphasis on specialist follow-up. The aim of this study was to determine the cause-specific mortality in ES and evaluate any relevant changes between 1977 and 2015. METHODS AND

RESULTS:

This is a retrospective, descriptive multicentre study. A total of 1546 patients (mean age 38.7 ± 15.4 years; 36% male) from 13 countries were included. Cause-specific mortality was examined before and after July 2006, 'early' and 'late', respectively. Over a median follow-up of 6.1 years (interquartile range 2.1-21.5 years) 558 deaths were recorded; cause-specific mortality was identified in 411 (74%) cases. Leading causes of death were heart failure (34%), infection (26%), sudden cardiac death (10%), thromboembolism (8%), haemorrhage (7%), and peri-procedural (7%). Heart failure deaths increased in the 'late' relative to the 'early' era (P = 0.032), whereas death from thromboembolic events and death in relation to cardiac and non-cardiac procedures decreased (P = 0.014, P = 0.014, P = 0.004, respectively). There was an increase in longevity in the 'late' vs. 'early' era (median survival 52.3 vs. 35.2 years, P < 0.001).

CONCLUSION:

The study shows that despite changes in therapy, care, and follow-up of ES in tertiary care centres, all-cause mortality including cardiac remains high. Patients from the 'late' era, however, die later and from chronic rather than acute cardiac causes, primarily heart failure, whereas peri-procedural and deaths due to haemoptysis have become less common. Lifelong vigilance in tertiary centres and further research for ES are clearly needed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complexo de Eisenmenger Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complexo de Eisenmenger Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article